Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination

Heung Kang Tae, Hyup Lee Jin, Kil Song Chung, Dong Han Hee, Cheol Shin Byung, Sara I. Pai, Chien Fu Hung, Cornelia Trimble, Jong Seok Lim, Tae Woo Kim, T. C. Wu

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Immunotherapy and chemotherapy are generally effective against small tumors in animal models of cancer. However, these treatment regimens are generally ineffective against large, bulky tumors. We have found that a multimodality treatment regimen using DNA vaccination in combination with chemotherapeutic agent epigallocatechin-3-gallate (EGCG), a compound found in green tea, is effective in inhibiting large tumor growth. EGCG was found to induce tumor cellular apoptosis in a dose-dependent manner. The combination of EGCG and DNA vaccination led to an enhanced tumor-specific T-cell immune response and enhanced antitumor effects, resulting in a higher cure rate than either immunotherapy or EGCG alone. In addition, combined DNA vaccination and oral EGCG treatment provided long-term antitumor protection in cured mice. Cured animals rejected a challenge of E7-expressing tumors, such as TC-1 and B16E7, but not a challenge of B16 7 weeks after the combined treatment, showing antigen-specific immune responses. These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments.

Original languageEnglish
Pages (from-to)802-811
Number of pages10
JournalCancer Research
Volume67
Issue number2
DOIs
Publication statusPublished - 2007 Jan 15

Fingerprint

Cellular Immunity
Vaccination
T-Lymphocytes
DNA
Neoplasms
Immunotherapy
Therapeutics
epigallocatechin gallate
Histocompatibility Antigens Class II
Tea
Animal Models
Apoptosis
Drug Therapy
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tae, H. K., Jin, H. L., Chung, K. S., Hee, D. H., Byung, C. S., Pai, S. I., ... Wu, T. C. (2007). Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Research, 67(2), 802-811. https://doi.org/10.1158/0008-5472.CAN-06-2638

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. / Tae, Heung Kang; Jin, Hyup Lee; Chung, Kil Song; Hee, Dong Han; Byung, Cheol Shin; Pai, Sara I.; Hung, Chien Fu; Trimble, Cornelia; Lim, Jong Seok; Kim, Tae Woo; Wu, T. C.

In: Cancer Research, Vol. 67, No. 2, 15.01.2007, p. 802-811.

Research output: Contribution to journalArticle

Tae, HK, Jin, HL, Chung, KS, Hee, DH, Byung, CS, Pai, SI, Hung, CF, Trimble, C, Lim, JS, Kim, TW & Wu, TC 2007, 'Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination', Cancer Research, vol. 67, no. 2, pp. 802-811. https://doi.org/10.1158/0008-5472.CAN-06-2638
Tae, Heung Kang ; Jin, Hyup Lee ; Chung, Kil Song ; Hee, Dong Han ; Byung, Cheol Shin ; Pai, Sara I. ; Hung, Chien Fu ; Trimble, Cornelia ; Lim, Jong Seok ; Kim, Tae Woo ; Wu, T. C. / Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. In: Cancer Research. 2007 ; Vol. 67, No. 2. pp. 802-811.
@article{af3b8d2fc70f43b9a944ffb1c818e19f,
title = "Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination",
abstract = "Immunotherapy and chemotherapy are generally effective against small tumors in animal models of cancer. However, these treatment regimens are generally ineffective against large, bulky tumors. We have found that a multimodality treatment regimen using DNA vaccination in combination with chemotherapeutic agent epigallocatechin-3-gallate (EGCG), a compound found in green tea, is effective in inhibiting large tumor growth. EGCG was found to induce tumor cellular apoptosis in a dose-dependent manner. The combination of EGCG and DNA vaccination led to an enhanced tumor-specific T-cell immune response and enhanced antitumor effects, resulting in a higher cure rate than either immunotherapy or EGCG alone. In addition, combined DNA vaccination and oral EGCG treatment provided long-term antitumor protection in cured mice. Cured animals rejected a challenge of E7-expressing tumors, such as TC-1 and B16E7, but not a challenge of B16 7 weeks after the combined treatment, showing antigen-specific immune responses. These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments.",
author = "Tae, {Heung Kang} and Jin, {Hyup Lee} and Chung, {Kil Song} and Hee, {Dong Han} and Byung, {Cheol Shin} and Pai, {Sara I.} and Hung, {Chien Fu} and Cornelia Trimble and Lim, {Jong Seok} and Kim, {Tae Woo} and Wu, {T. C.}",
year = "2007",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-06-2638",
language = "English",
volume = "67",
pages = "802--811",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination

AU - Tae, Heung Kang

AU - Jin, Hyup Lee

AU - Chung, Kil Song

AU - Hee, Dong Han

AU - Byung, Cheol Shin

AU - Pai, Sara I.

AU - Hung, Chien Fu

AU - Trimble, Cornelia

AU - Lim, Jong Seok

AU - Kim, Tae Woo

AU - Wu, T. C.

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Immunotherapy and chemotherapy are generally effective against small tumors in animal models of cancer. However, these treatment regimens are generally ineffective against large, bulky tumors. We have found that a multimodality treatment regimen using DNA vaccination in combination with chemotherapeutic agent epigallocatechin-3-gallate (EGCG), a compound found in green tea, is effective in inhibiting large tumor growth. EGCG was found to induce tumor cellular apoptosis in a dose-dependent manner. The combination of EGCG and DNA vaccination led to an enhanced tumor-specific T-cell immune response and enhanced antitumor effects, resulting in a higher cure rate than either immunotherapy or EGCG alone. In addition, combined DNA vaccination and oral EGCG treatment provided long-term antitumor protection in cured mice. Cured animals rejected a challenge of E7-expressing tumors, such as TC-1 and B16E7, but not a challenge of B16 7 weeks after the combined treatment, showing antigen-specific immune responses. These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments.

AB - Immunotherapy and chemotherapy are generally effective against small tumors in animal models of cancer. However, these treatment regimens are generally ineffective against large, bulky tumors. We have found that a multimodality treatment regimen using DNA vaccination in combination with chemotherapeutic agent epigallocatechin-3-gallate (EGCG), a compound found in green tea, is effective in inhibiting large tumor growth. EGCG was found to induce tumor cellular apoptosis in a dose-dependent manner. The combination of EGCG and DNA vaccination led to an enhanced tumor-specific T-cell immune response and enhanced antitumor effects, resulting in a higher cure rate than either immunotherapy or EGCG alone. In addition, combined DNA vaccination and oral EGCG treatment provided long-term antitumor protection in cured mice. Cured animals rejected a challenge of E7-expressing tumors, such as TC-1 and B16E7, but not a challenge of B16 7 weeks after the combined treatment, showing antigen-specific immune responses. These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments.

UR - http://www.scopus.com/inward/record.url?scp=33846697356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846697356&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2638

DO - 10.1158/0008-5472.CAN-06-2638

M3 - Article

VL - 67

SP - 802

EP - 811

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -